RESUMO
SOX7 belongs to the SOX gene family.And it has been shown to regulate multiple biological processes.Studies have found that SOX7 gene is likely to be a tumor suppressor gene.In many tumors,SOX7 downregulation that inhibits proliferation,migration and invation of tumor via regulating the Wnt-β-catenin signaling pathway mediated the transcription process,which plays a significant role in tumorigenesis.
RESUMO
It is found that gambogic acid can play anti-tumor effects through different mechanisms in a variety of tumor cells,including induce apoptosis,inhibit telomerase and topoisomerase activity,inhibit the expression of heat shock protein and channel protein,inhibit tumor angiogenesis and metastasis and reverse multidrug resistance.Gambogic acid is expected to become a new anti-tumor drug,still need to be further explored its value in the field of anti-tumor.
RESUMO
Studies show that some Trim family proteins are associated with tumorigenesis and cancer progression.Trim members are differently expressed in various cancers including lung cancer,hepatocellular carcinoma,colon cancer,stomach cancer and breast cancer.Trim proteins are found to be involved in tumor progess by modulating the expression of tumor associated genes via several signaling pathways such as p53 and NF-κB pathway.Members of Trim family can be used as oncogenes or anti-oncogenes in the biological processes such as tumor cell proliferation,cell differentiation,cell apoptosis and metastasis.
RESUMO
Objective To evaluatc the efficacy and safcty of recombinant endostatin (Endostar)combined with concurrent radio-chemotherapy (CRCT) in patients with unresectable stage Ⅲ non-small cell lung cancer (NSCLC).Methods From March 2009 to November 2011,47 patients received threedimensional conformal radiotherapy of 60-66 Gy in 30-33 fractions over 6-7 weeks And concurrent chemotherapy of docetaxel 65 mg/m2 and cisplatin 65 mg/m2.Endostar was administered once a week before and on week 2,4,6 during CRCT at a dose level of 7.5 mg/m2/d.Tumor response was evaluated with thoracic CT scans performed 4 weeks after completion of treatment in accordance with RECIST 1.1 criteria.Acute toxicities were evaluated in accordance with CTCAE 3.0.Results Forty-four patients completed treatment and toxicity evaluation,42 patients completed evaluation of efficacy.Five patients achieved complete response,29 partial response,3 stable disease,and 5 progressive disease,2 were net assessed.Overall response rate was 77％.One-year overall survival rate was 81％,and one-year progression-free survival rate was 51％.Twelve patients died,2 died of treatment related toxicities,8 of cancer,and 2 of unknown causes.Nineteen patients developed grade 3/4 neutrocytopenia,grade 3 acute esophagitis and pneumonitis were observed in 4 and 4 patients,respectively,and 1 patient died of pneumonitis.No patient developed cardiovascular toxicities and hemorrhage.Conclusions Endostar combined with CRCT for unresectable stage Ⅲ NSCLC was safe and the short term outcomes were promising.Further investigations are warranted.